Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Stephanie J. Lee, Mukta Arora, Zachariah Defilipp, Mohammad Issam Abu Zaid, Antonio Di Stasi, Vedran Radojcic, Michael L. Meyers, Hope Qamoos, Peter Ordentlich, Christine Quaranto, Aaron Schmitt, Yu Gu, Amandeep Salhotra, Iskra Pusic, Carrie Lynn Kitko

Blood (2021) 138 (Supplement 1): 263.

https://doi.org/10.1182/blood-2021-146050

Published: 2021

Journal Articles

A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Peter Hillmen, MBChB, PhD FRCP, FRCPath, Hope Qamoos, CNP, Anne Uyei, MD, Wayne M. Rothbaum, Wojciech Jurczak, MD PhD, Catherine Thieblemont, MD PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134901

Published: 2020

Journal Articles

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

John Mascarenhas, MD, Alessandro M. Vannucchi, MD, Adam J. Mead, MD PhD, Regina Garcia-Delgado, MD, Andrzej Pluta, MD, Hope Qamoos, CNP, Anne Uyei, MD, Damaj Gandhi Laurent, MD PhD, Haifa K Al-Ali

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-134262

Published: 2020